A novel prognostic and therapeutic target biomarker based on complement-related gene signature in gastric cancer

Zuming Liu; Mingwei Yang; Hang Shu; Jianmei Zhou

doi:10.21037/tcr-23-628

A novel prognostic and therapeutic target biomarker based on complement-related gene signature in gastric cancer

Transl Cancer Res. 2023 Dec 31;12(12):3565-3580. doi: 10.21037/tcr-23-628. Epub 2023 Dec 6.

Authors

Zuming Liu^#¹, Mingwei Yang^#², Hang Shu³, Jianmei Zhou^{1

4}

Affiliations

¹ Digestive Department, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, China.
² Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
³ Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
⁴ Department of Infectious Diseases, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.

^# Contributed equally.

Abstract

Background: Gastric cancer (GC) is one of the most prevalent cancer types that reduce human life expectancy. The current tumor-node-metastasis (TNM) staging system is inadequate in identifying higher or lower risk of GC patients because of tumor heterogeneity. Research shows that complement plays a dual role in the tumor development and progression of GC.

Methods: We downloaded GC data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). A complement-related risk signature was constructed through bioinformatics analysis. Subsequently, the predictive ability of this signature was validated with GSE84437 dataset, and a nomogram integrating risk score and common clinical factors was established. Besides, we evaluated the association of risk score with the immune and stromal cell infiltration in TCGA. Furthermore, immunotherapy response prediction and drug susceptibility analysis were conducted to access the ability of the risk signature in predicting the therapeutic effect.

Results: A complement-related gene (CRG) signature, based on six genes (SPLG, C9, ITIH1, ZFPM2, CD36, and SERPINE1), was established. In both the training and validation sets, the overall survival of GC patients in the high-risk group was lower than that of the low-risk group, and the nomogram to predict the 1-, 2-, and 3-year survival rates of GC patients was developed. In addition, CIBERSORT algorithm showed the high-risk patients had higher levels of immune cell infiltration than low-risk patients, and the ESTIMATE results implied that the high-risk group had more stromal component in tumor microenvironment. Besides, compared to the low-risk group, there were higher expressions of most immune checkpoint genes and HLA genes in the high-risk group, and the high-risk patients showed higher sensitivity to the chemotherapy and targeted drugs (axitinib, dasatinib, pazopanib, saracatinib, sunitinib and temsirolimus).

Conclusions: The novel CRG signature may act as a reliable, efficient tool for prognostic prediction and treatment guidance in future clinical practice.

Keywords: Gastric cancer (GC); complement; overall survival analysis (OS analysis); prognosis; treatment.